JP2017526744A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526744A5 JP2017526744A5 JP2017528765A JP2017528765A JP2017526744A5 JP 2017526744 A5 JP2017526744 A5 JP 2017526744A5 JP 2017528765 A JP2017528765 A JP 2017528765A JP 2017528765 A JP2017528765 A JP 2017528765A JP 2017526744 A5 JP2017526744 A5 JP 2017526744A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- peg
- antifolate
- poly
- dspe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 41
- 239000002502 liposome Substances 0.000 claims 36
- 239000004052 folic acid antagonist Substances 0.000 claims 33
- 230000003432 anti-folate effect Effects 0.000 claims 27
- 229940127074 antifolate Drugs 0.000 claims 27
- 229920001223 polyethylene glycol Polymers 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 239000002202 Polyethylene glycol Substances 0.000 claims 12
- 230000000975 bioactive effect Effects 0.000 claims 12
- 239000007864 aqueous solution Substances 0.000 claims 11
- 239000003381 stabilizer Substances 0.000 claims 11
- 239000003937 drug carrier Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 7
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 7
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 7
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 7
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 7
- 235000012000 cholesterol Nutrition 0.000 claims 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 6
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 6
- 229920002401 polyacrylamide Polymers 0.000 claims 6
- -1 DSPE-PEG-maleimide Chemical compound 0.000 claims 4
- 239000012867 bioactive agent Substances 0.000 claims 4
- 102000006815 folate receptor Human genes 0.000 claims 4
- 108020005243 folate receptor Proteins 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- 150000008575 L-amino acids Chemical class 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 229920006187 aquazol Polymers 0.000 claims 3
- 239000012861 aquazol Substances 0.000 claims 3
- 229920005601 base polymer Polymers 0.000 claims 3
- 229960001438 immunostimulant agent Drugs 0.000 claims 3
- 239000003022 immunostimulating agent Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 230000007935 neutral effect Effects 0.000 claims 3
- 229920000773 poly(2-methyl-2-oxazoline) polymer Polymers 0.000 claims 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims 3
- 229920002187 poly[N-2-(hydroxypropyl) methacrylamide] polymer Polymers 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims 2
- 229920002498 Beta-glucan Polymers 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 102000010449 Folate receptor beta Human genes 0.000 claims 2
- 108050001930 Folate receptor beta Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 2
- 102100023119 Sperm-egg fusion protein Juno Human genes 0.000 claims 2
- 101710093389 Sperm-egg fusion protein Juno Proteins 0.000 claims 2
- 229960003896 aminopterin Drugs 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 239000003125 aqueous solvent Substances 0.000 claims 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 2
- 239000001639 calcium acetate Substances 0.000 claims 2
- 229960005147 calcium acetate Drugs 0.000 claims 2
- 235000011092 calcium acetate Nutrition 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical group N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 claims 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical group C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 claims 2
- 239000003944 phosphoribosylglycinamide formyltransferase inhibitor Substances 0.000 claims 2
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 claims 2
- 229960000214 pralatrexate Drugs 0.000 claims 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims 2
- 229960005385 proguanil Drugs 0.000 claims 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims 2
- 229960000611 pyrimethamine Drugs 0.000 claims 2
- 150000004944 pyrrolopyrimidines Chemical class 0.000 claims 2
- 239000001632 sodium acetate Substances 0.000 claims 2
- 235000017281 sodium acetate Nutrition 0.000 claims 2
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 claims 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 229920001503 Glucan Polymers 0.000 claims 1
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229950000909 lometrexol Drugs 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000004882 non-tumor cell Anatomy 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 1
- 229960001082 trimethoprim Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037597P | 2014-08-14 | 2014-08-14 | |
| US62/037,597 | 2014-08-14 | ||
| US201562130493P | 2015-03-09 | 2015-03-09 | |
| US62/130,493 | 2015-03-09 | ||
| US201562133265P | 2015-03-13 | 2015-03-13 | |
| US62/133,265 | 2015-03-13 | ||
| PCT/US2015/045353 WO2016025882A2 (en) | 2014-08-14 | 2015-08-14 | Liposome encapsulated affinity drug |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526744A JP2017526744A (ja) | 2017-09-14 |
| JP2017526744A5 true JP2017526744A5 (enExample) | 2018-09-20 |
| JP6825764B2 JP6825764B2 (ja) | 2021-02-03 |
Family
ID=55304769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528765A Active JP6825764B2 (ja) | 2014-08-14 | 2015-08-14 | リポソームカプセル化親和性薬物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160228573A1 (enExample) |
| EP (1) | EP3188724B1 (enExample) |
| JP (1) | JP6825764B2 (enExample) |
| KR (1) | KR102505508B1 (enExample) |
| CN (2) | CN106794164A (enExample) |
| AP (1) | AP2017009766A0 (enExample) |
| AU (4) | AU2015301462B2 (enExample) |
| BR (1) | BR112017002767B1 (enExample) |
| CA (1) | CA2957775C (enExample) |
| DK (1) | DK3188724T3 (enExample) |
| EA (1) | EA201790378A1 (enExample) |
| ES (1) | ES2905498T3 (enExample) |
| MA (1) | MA40428A (enExample) |
| MX (1) | MX386433B (enExample) |
| WO (1) | WO2016025882A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2731524T3 (es) | 2012-04-05 | 2019-11-15 | Massachusetts Inst Technology | Composiciones inmunoestimuladoras y métodos de uso de las mismas |
| WO2017048860A1 (en) | 2015-09-14 | 2017-03-23 | Vgsk Technologies, Inc. | A sterically stabilized carrier for subcutaneous, sublingual and oral therapeutics, compositions and methods for treating a mammal |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| WO2018031980A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| US20180236098A1 (en) * | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| EP3496757A4 (en) * | 2016-08-12 | 2020-04-15 | L.E.A.F Holdings Group LLC | POLYGLUTAMATE ANTIFOLATES AND USES THEREOF. |
| CN106750252B (zh) * | 2016-12-05 | 2018-11-30 | 山东大学齐鲁医院 | 二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000-双叶酸及其制备方法和应用 |
| WO2018187728A1 (en) * | 2017-04-07 | 2018-10-11 | Maa Laboratories, Inc. | Methods of improving the solubility and bioavailability of therapeutic agents |
| EP3615005B1 (en) * | 2017-04-28 | 2025-07-30 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Compositions and methods for vaccine delivery |
| US12246019B2 (en) * | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| US12076402B2 (en) | 2018-02-07 | 2024-09-03 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| EP3749318A4 (en) * | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| WO2019157145A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pemetrexed and uses thereof |
| US12310966B2 (en) * | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| EP3749317A4 (en) * | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
| EP3749321A4 (en) * | 2018-02-07 | 2022-03-09 | L.E.A.F Holdings Group LLC | Gamma polyglutamated antifolates and uses thereof |
| JP7491573B2 (ja) * | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| CA3090506A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated tetrahydrofolates and uses thereof |
| US11730738B2 (en) | 2018-02-07 | 2023-08-22 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CA3090989A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| CA3090753A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| EP3752158A4 (en) * | 2018-02-14 | 2022-03-09 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF |
| WO2019160734A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| WO2019160735A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| GB201814959D0 (en) * | 2018-09-14 | 2018-10-31 | Secr Defence | Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses |
| US12453777B2 (en) | 2019-03-20 | 2025-10-28 | Massachusetts Institute Of Technology | Uses of amphiphiles in immune cell therapy and compositions therefor |
| CN118203546A (zh) * | 2019-05-07 | 2024-06-18 | 米尼翁大学 | 生产脂质体的方法 |
| WO2020257260A1 (en) | 2019-06-17 | 2020-12-24 | Massachusetts Institute Of Technology | Formulation of peptide loaded liposomes and related applications |
| US20230270881A1 (en) * | 2020-01-21 | 2023-08-31 | University Of Virginia Patent Foundation | Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer |
| WO2022081838A1 (en) * | 2020-10-14 | 2022-04-21 | Georgia Tech Research Corporation | Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof |
| CA3217928A1 (en) | 2021-05-05 | 2022-11-10 | Kameswari S. Konduri | Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation |
| WO2025005632A1 (ko) * | 2023-06-26 | 2025-01-02 | 주식회사 무진메디 | 이온화 가능한 펩타이드를 이용한 지질 나노입자 기반 약물 전달체 및 이의 제조방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| NZ534378A (en) * | 2002-02-22 | 2006-10-27 | Schering Corp | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same |
| US20100210745A1 (en) * | 2002-09-09 | 2010-08-19 | Reactive Surfaces, Ltd. | Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes |
| CN1938048B (zh) * | 2004-03-26 | 2010-05-12 | 泰尔茂株式会社 | 脂质体制剂 |
| US20110022529A1 (en) | 2009-07-22 | 2011-01-27 | Fernando Barsoba | Social network creation using image recognition |
| US8747869B2 (en) * | 2010-03-19 | 2014-06-10 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| WO2011150392A1 (en) * | 2010-05-28 | 2011-12-01 | Purdue Research Foundation | Delivery of therapeutic agents to inflamed tissues using folate-targeted agents |
| WO2012031205A2 (en) * | 2010-09-03 | 2012-03-08 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
| EP2614084A4 (en) * | 2010-09-09 | 2014-02-19 | Purdue Research Foundation | HUMANE FOLAT RECEPTOR BETA ANTIBODIES AND METHOD FOR THEIR USE |
| JP6049712B2 (ja) * | 2011-07-08 | 2016-12-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ | 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子 |
| HRP20201465T1 (hr) * | 2011-07-13 | 2021-02-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomi koji ko-inkapsuliraju bisfosfonat i amfipatsko sredstvo |
| US20130122096A1 (en) * | 2011-11-14 | 2013-05-16 | Silenseed Ltd. | Compositions for drug delivery and methods of manufacturing and using same |
| WO2013084208A2 (pt) * | 2011-12-07 | 2013-06-13 | Universidade Do Minho | Lipossomas e respetivo método de produção |
| US20140120157A1 (en) * | 2012-09-19 | 2014-05-01 | Georgetown University | Targeted liposomes |
-
2015
- 2015-08-14 WO PCT/US2015/045353 patent/WO2016025882A2/en not_active Ceased
- 2015-08-14 AP AP2017009766A patent/AP2017009766A0/en unknown
- 2015-08-14 ES ES15832081T patent/ES2905498T3/es active Active
- 2015-08-14 EP EP15832081.2A patent/EP3188724B1/en active Active
- 2015-08-14 US US14/826,967 patent/US20160228573A1/en not_active Abandoned
- 2015-08-14 BR BR112017002767-4A patent/BR112017002767B1/pt active IP Right Grant
- 2015-08-14 CN CN201580054566.5A patent/CN106794164A/zh active Pending
- 2015-08-14 MA MA040428A patent/MA40428A/fr unknown
- 2015-08-14 JP JP2017528765A patent/JP6825764B2/ja active Active
- 2015-08-14 AU AU2015301462A patent/AU2015301462B2/en active Active
- 2015-08-14 MX MX2017001881A patent/MX386433B/es unknown
- 2015-08-14 CA CA2957775A patent/CA2957775C/en active Active
- 2015-08-14 DK DK15832081.2T patent/DK3188724T3/da active
- 2015-08-14 EA EA201790378A patent/EA201790378A1/ru unknown
- 2015-08-14 CN CN202310777450.0A patent/CN117159470A/zh active Pending
- 2015-08-14 KR KR1020177006638A patent/KR102505508B1/ko active Active
-
2020
- 2020-05-19 AU AU2020203241A patent/AU2020203241A1/en not_active Abandoned
-
2022
- 2022-03-24 AU AU2022202046A patent/AU2022202046A1/en not_active Abandoned
-
2024
- 2024-06-05 US US18/734,619 patent/US20250066468A1/en active Pending
- 2024-08-02 AU AU2024205501A patent/AU2024205501A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526744A5 (enExample) | ||
| JP2019524885A5 (enExample) | ||
| JP2019524802A5 (enExample) | ||
| KR102584446B1 (ko) | 알파 및 감마-d 폴리글루타메이트화 항엽산 및 이의 용도 | |
| JP2025072362A5 (enExample) | ||
| O Elzoghby et al. | Natural polymeric nanoparticles for brain-targeting: implications on drug and gene delivery | |
| Urban et al. | Nanotools for the delivery of antimicrobial peptides | |
| US20170232115A1 (en) | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof | |
| KR20160110410A (ko) | 하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도 | |
| JP2016513090A5 (enExample) | ||
| JPWO2019157138A5 (enExample) | ||
| JPWO2019157145A5 (enExample) | ||
| JPWO2019160735A5 (enExample) | ||
| JPWO2019157146A5 (enExample) | ||
| JPWO2019157148A5 (enExample) | ||
| JPWO2019157120A5 (enExample) | ||
| US20210393799A1 (en) | Dendritic polymers complexed with immune checkpoint inhibitors for enhanced cancer immunotherapy | |
| Zhang et al. | Advances in long-circulating drug delivery strategy | |
| JPWO2019157125A5 (enExample) | ||
| Talevi et al. | Applications of nanosystems to anticancer drug therapy (Part I. Nanogels, nanospheres, nanocapsules) | |
| Shi et al. | Advances in nanotherapy for targeting senescent cells | |
| Zhang et al. | Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene‐dependent multidrug resistance | |
| US20230270882A1 (en) | Peptide-nanoparticle conjugates | |
| Singh et al. | Delivery systems for lymphatic targeting | |
| CN111107842A (zh) | 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒 |